More extensive analyses of non-myogenic sarcomas, carcinomas and tumors with a mixed phenotype are required to determine whether immunoreactivity for filensin and CP49 is, in fact, diagnostic of tumors with properties of skeletal muscle. This evidence concerns the gene BFSP2 and carcinoma.